Evidence map›Paper›PMID 29783765›Full record

ArticleMolecules (Basel, Switzerland)2018

1,2,6-Thiadiazinones as Novel Narrow Spectrum Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CaMKK2) Inhibitors.

Christopher R M Asquith, Paulo H Godoi, Rafael M Couñago, Tuomo Laitinen, John W Scott, Christopher G Langendorf, Jonathan S Oakhill, David H Drewry, William J Zuercher, Panayiotis A Koutentis and 2 more

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Novel Mono-Substituted 4International journal of molecular sciences · 2025
    Article
  2. Review
  3. Molecular Mechanisms Underlying CaInternational journal of molecular sciences · 2022
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Christopher R M AsquithStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. chris.asquith@unc.edu.ORCID 0000-0001-5871-3458
Paulo H GodoiStructural Genomics Consortium, Universidade Estadual de Campinas-UNICAMP, Campinas, São Paulo 13083-886, Brazil. phgodoi@yahoo.com.ORCID 0000-0003-1859-3513
Rafael M CouñagoStructural Genomics Consortium, Universidade Estadual de Campinas-UNICAMP, Campinas, São Paulo 13083-886, Brazil. rafaelcounago@gmail.com.
Tuomo LaitinenSchool of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, 70211 Kuopio, Finland. tuomo.laitinen@uef.fi.ORCID 0000-0003-1539-2142
John W ScottSt Vincent's Institute and Department of Medicine, University of Melbourne, 41 Victoria Parade, Fitzroy 3065, Australia. jscott@svi.edu.au.ORCID 0000-0002-1896-9798
Christopher G LangendorfSt Vincent's Institute and Department of Medicine, University of Melbourne, 41 Victoria Parade, Fitzroy 3065, Australia. clangendorf@svi.edu.au.
Jonathan S OakhillSt Vincent's Institute and Department of Medicine, University of Melbourne, 41 Victoria Parade, Fitzroy 3065, Australia. joakhill@svi.edu.au.
David H DrewryStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. david.drewry@unc.edu.
William J ZuercherStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. william.zuercher@unc.edu.ORCID 0000-0002-9836-0068
Panayiotis A KoutentisDepartment of Chemistry, University of Cyprus, P. O. Box 20537, 1678 Nicosia, Cyprus. koutenti@ucy.ac.cy.ORCID 0000-0002-4652-7567
Timothy M WillsonStructural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. tim.willson@unc.edu.
Andreas S KalogirouDepartment of Chemistry, University of Cyprus, P. O. Box 20537, 1678 Nicosia, Cyprus. kalogirou.andreas@ucy.ac.cy.

Funding

Creation of in vivo active chemical probes for CAMKK2 to treat cancerR01CA218442 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DREWRY, DAVID HAROLD · 2017 to 2019
$2.0M
NCI NIH HHS R01 CA218442Wellcome Trust
6 · The paper itself

Abstract

We demonstrate for the first time that 4

Indexed as

Calcium-Calmodulin-Dependent Protein Kinase KinaseCatalytic DomainCrystallography, X-RayHumansModels, MolecularMolecular Docking SimulationMolecular StructureProtein Kinase InhibitorsThiadiazolesWaterCalcium-Calmodulin-Dependent Protein Kinase KinaseCAMKK2 protein, humanProtein Kinase InhibitorsThiadiazolesWaterCaMKK2hinge binderkinase inhibitor designkinase water networkthiadiazinone

Identifiers

PMID29783765
PMCPMC6019134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.